Speeding Drugs to Market

Posted: 04/30/16

The FDA has created several new pathways that can shorten the time it takes for needed new medicines to receive regulatory approval. These pathways certainly benefit patients that need these medicines by getting them to market more quickly, and they also can benefit drug developers by providing a more rapid return on investment. However, meeting new FDA requirements can be a complicated and tricky business. PAREXEL is a leading international drug consulting firm, and the Bloom Group helped PAREXEL Vice President Barry Farrimond, Network for Excellence in Health Innovation President Jonathan Fleming, and PAREXEL expert Mark Mathieu place their article “FDA’s Accelerated Pathways Are the New Normal” in DIA, the publication of the Drug Information Association, here.